| Biomarker ID | 378 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | Methylation Status of RASSF1 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR = 1.354 (95% CI: 0.813- 2.464) |
| Effect on Pathways | Pathways Include:-Bladder cancer,Non-small cell lung cancer,p53 activity regulation,Pathways in cancer |
| Experiment | Benign vs. PCA |
| Type of Biomarker | Diagnostic |
| Cohort | Of the 74 specimen cohort, only the 63 that yielded >300 ng total nucleic acid were used for DNA methylation analysis.Out of which 33 had Benign tumors and 30 had PCA. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.641 (95% CI: 0.504- 0.777) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RASSF1 |